A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine

This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of RVX-sCPD9, given Intranasally (IN), as a booster dose to previously vaccinated healthy adults. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating four dose levels of RVX-sCPD9 administered IN (10\^2, 10\^3, 10\^4, 5 x 10\^4 FFU). A sample size of 80 participants (20 participants in each cohort). The primary objective is to evaluate the safety and reactogenicity of a single IN administration of 4 ascending dosages of RVX-sCPD9 in previously vaccinated healthy adults.

NCT Number	NCT07703475
Lead Sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Conditions	COVID -19
Enrollment	80 participants
Start Date	2026-08-15
Primary Completion	2027-11-15 (estimated)
Study Completion	2027-11-15 (estimated)
Updated on ClinicalTrials.gov	2026-08-14